Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company
specializing in highly effective, non-invasive, minimally-invasive
and cost-effective treatments for oncological and non-oncological
conditions, is pleased to announce the following promotions and
appointments to its management team:
- Maggie Martinez has been promoted to Chief Operating
Officer
- Emiliano Sosa has been promoted to Chief Technical Officer
- Stephanie Tipton has been promoted to Vice President of
Marketing
- Sean Delaney has been appointed Vice President of Regulatory
and Quality Assurance
- Wayne Lura has been appointed Vice President of Aesthetic
Sales
Ms. Martinez joined Sensus nine years ago and
subsequently held positions of increasing responsibility.
Most recently she served as Vice President of Operations, and in
her new role as COO she will be responsible for all aspects of
customer support and satisfaction, vendor relations, intra-company
communication and processes. Ms. Martinez holds a B. S.
degree in marketing from Stetson University in DeLand, Florida.
Mr. Sosa joined Sensus last year as Vice
President of Technology Development with extensive experience in
banking, cyber security and artificial intelligence. Among his
accomplishments are the introduction and engineering of the
first GPS device in the Argentina market with real time streaming
video cameras for vehicles (founding Overmax S.A.). His company in
the U.S. was recognized as 2016 small business of the year. He has
also designed and developed electroencephalography and brain
mapping devices, implementing the first 3-D EEG Brain Mapping
medical devices and polysomnographs at the time. In his new
position he is charged with overseeing and expanding the company’s
team of engineers to provide dependable and differentiated
technologies to customers and their patients. A priority focus will
be on expanding the capabilities and indications of the company’s
Sentinel™ technology. Sentinel provides asset management and
HIPAA-compliant patient data and storage capability, and also
contains the software necessary to support shared service models
including direct patient billing. Mr. Sosa holds degrees in
information systems engineering from the National University of
Technology in Buenos Aires, and in international marketing and
foreign trade from the University of Buenos Aires in Argentina.
Ms. Tipton joined Sensus in June of 2021 as the
Director of Digital Marketing, revamping the company’s social media
and on-line outreach, which resulted in a dramatic increase in
patient and physician inquiries. She has also worked closely with
the company’s clinical, sales, and engineering teams to provide a
more comprehensive approach to the product portfolio. As an
experienced marketing professional with a record of success, she
was President of Tipton Group, a marketing consulting firm prior to
joining Sensus. Previously she was for six years Industrial
Director/Director of Sales for Nova Medical Centers in Knoxville,
Tenn. Ms. Tipton holds a B.S. degree in biology and business
administration from the University of Tennessee, Knoxville.
Mr. Delany brings to Sensus nearly 20 years of
product development experience in regulatory affairs, quality
assurance and regulatory compliance, including worldwide regulatory
clearances and approvals, development and product quality,
international standard compliance and post–market
surveillance. Much of his experience is in
software-controlled image-guided radiation therapy systems. Most
recently, Mr. Delaney worked at ViewRay, with responsibility for
regulatory affairs and compliance, quality assurance, radiation
safety and U.S. Food and Drug Administration submissions. He holds
a B.S. in physics from San Jose State University and an MBA from
Santa Clara University, Leavey School of Business.
Mr. Lura has two decades of experience in
medical aesthetics, bringing new products to market at such notable
companies as Cynosure, Eclipse Medical, DefenAge Skincare, Zimmer
Medical Systems, Cutera, and Lumenis. He will be responsible for
expanding Sensus’ aesthetics footprint as the company continues to
add to its product portfolio, and developing opportunities for
product introductions including developing a total solution bundle
for Sensus customers. Mr. Lura brings to Sensus deep
relationships with industry KOLs and dermatologists. He holds
a B.A. in communications from Concordia University Texas, attended
the United States Airforce Academy and was a commissioned Second
Lieutenant in the Air Force ROTC at the University of Texas,
Austin.
“Our history of growth, execution and expanding
market opportunities have made these staff changes both necessary
and prudent, including creating several new positions. I am
delighted to announce these promotions and appointments and look
forward to the contributions of these talented individuals as
Sensus executes on an aggressive business strategy,” said Joe
Sardano, chairman and chief executive officer of Sensus Healthcare.
“Maggie Martinez has proven over and over again her initiative,
drive and commitment to the company, our customers and patients and
I am proud of her appointment to Chief Operating Officer. In just a
short period of time, Emiliano Sosa has distinguished himself in
assembling a high-quality team of engineers who are adding
exceptional value to our technologies. His leadership skills
and technical acumen ideally qualify him to serve as our Chief
Technical Officer. Stephanie Tipton has been a creative force in
digital marketing for the company, and going forward she is charged
with assuming a leadership role in all aspects of marketing.
She will be instrumental in supporting the introduction of new
products to the marketplace, an important initiative for
Sensus.”
Mr. Sardano added, “Our anticipated growth has
necessitated the expansion of our senior management team. I’m
thrilled Sean Delany has joined Sensus as Vice President of
Regulatory and Quality Assurance. Sean comes to us with deep
experience navigating regulatory pathways not only in the U.S., but
in all of Asia, the EU and South America. His knowledge will
be valuable as we work to secure regulatory clearances for our
products – both existing and new – around the world.
Additionally, we look forward to even greater success with our
growing aesthetics product portfolio with Wayne Lura at the
helm. His appointment underscores our plans to expand our
aesthetic footprint with innovative products. Wayne has a wealth of
contacts and enjoys excellent relationships with the leaders in
aesthetic medicine.
“Our goal is for Sensus to be a destination for
great employees from all walks of life and backgrounds. I am proud
of our diverse and talented workforce, all contributing to our
success with an unwavering commitment to quality, innovation,
teamwork, respect and customer service,” Mr. Sardano concluded.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device
company specializing in highly effective, non-invasive, minimally
invasive and cost-effective treatments for both oncological and
non-oncological conditions. Sensus offers its proprietary
low-energy X-ray technology known as superficial radiation therapy
(SRT), which is the culmination of more than a decade of research
and development, to treat non-melanoma skin cancers and keloids
with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its
portfolio of innovative medical device products, including
aesthetic lasers and its needleless TransDermal Infusion System™,
Sensus provides revolutionary treatment options to enhance the
quality of life of patients around the world.
For more information, visit
www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are
or may be deemed ''forward-looking statements.'' In some cases,
these statements can be identified by the use of forward-looking
terminology such as "believes," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should," “approximately,” "potential" or negative or other
variations of those terms or comparable terminology, although not
all forward-looking statements contain these words.
Forward-looking statements involve risks and
uncertainties because they relate to events, developments, and
circumstances relating to Sensus, our industry, and/or general
economic or other conditions that may or may not occur in the
future or may occur on longer or shorter timelines or to a greater
or lesser degree than anticipated. Although we believe that we have
a reasonable basis for each forward-looking statement contained in
this press release, forward-looking statements are not guarantees
of future performance, and our actual results of operations,
financial condition and liquidity, and the development of the
industry in which we operate may differ materially from the forward
looking statements contained in this press release, as a result of
the following factors, among others: the continuation and severity
of the COVID-19 pandemic, including its impact on sales and
marketing; our ability to achieve profitability; our ability to
obtain and maintain the intellectual property needed to adequately
protect our products, and our ability to avoid infringing or
otherwise violating the intellectual property rights of third
parties; the level and availability of government and/or third
party payor reimbursement for clinical procedures using our
products, and the willingness of healthcare providers to purchase
our products if the level of reimbursement declines; the regulatory
requirements applicable to us and our competitors; our ability to
efficiently manage our manufacturing processes and costs; the risks
arising from doing business in China and other foreign countries;
legislation, regulation, or other governmental action that affects
our products, taxes, international trade regulation, or other
aspects of our business; concentration of our customers in the U.S.
and China, including the concentration of sales to one particular
customer in the U.S.; and other risks described from time to time
in our filings with the Securities and Exchange Commission,
including our Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q. In addition, we note that our revenues and profits for
the year ended December 31, 2022 are subject to adjustments,
including adjustments that may be made in connection with the
completion of our audited financial statements.
At the present time, we do not expect that the
Russia-Ukraine conflict and global geopolitical uncertainty will
have any particular impact on our business, but we continue to
monitor developments and will address them in future disclosures,
if applicable.
In addition, even if future events,
developments, and circumstances are consistent with the
forward-looking statements contained in this press release, they
may not be predictive of results or developments in future periods.
Any forward-looking statements that we make in this press release
speak only as of the date of such statement, and we undertake no
obligation to update such statements to reflect events or
circumstances after the date of this press release, except as may
be required by applicable law. You should read carefully our
"Introductory Note Regarding Forward-Looking Information" and the
factors described in the "Risk Factors" section of our periodic
reports filed with the Securities and Exchange Commission to better
understand the risks and uncertainties inherent in our
business.
Contact:LHA Investor
RelationsKim Sutton Golodetz212-838-3777kgolodetz@lhai.com
# # #
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
From Oct 2023 to Oct 2024